Last reviewed · How we verify
r-metHuLeptin
At a glance
| Generic name | r-metHuLeptin |
|---|---|
| Also known as | metreleptin, Recombinant leptin |
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy (PHASE2)
- Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy (PHASE3)
- Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
- Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy (PHASE3)
- Expanded Access Metreleptin Study
- MEASuRE: Metreleptin Effectiveness And Safety Registry
- Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy (PHASE3)
- Metreleptin in Anorexia Nervosa (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- r-metHuLeptin CI brief — competitive landscape report
- r-metHuLeptin updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI